Enriched GO terms included processes such as “Phosphorylation” (e.g., SMG1, GSK3A, DYRK2), “Peptidyl-Serine Phosphorylation” (e.g., TNKS, ROCK2), and “Peptidyl-Threonine Phosphorylation” (e.g., LMTK2, CDC42BPB) (Fig. 3G), highlighting molecular mechanisms that may contribute to the higher NFT burden in AD compared to PART (85). This evidence concerns the gene GSK3A and Alzheimer disease.